L3VLUP
ProSign in

NATR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NATRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NATR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNATRVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 20211 holders, $4.2m28 holders, $12.4bn
Q1 20221 holders, $5.7m23 holders, $16.1bn
Q2 20221 holders, $4.9m25 holders, $18.1bn
Q3 20221 holders, $4.2m22 holders, $18.4bn
Q4 20221 holders, $4.1m28 holders, $18.4bn
Q1 20231 holders, $5.1m26 holders, $21.4bn
Q2 20231 holders, $6.7m27 holders, $24.7bn
Q3 20231 holders, $8.0m33 holders, $24.3bn
Q4 20231 holders, $8.1m32 holders, $28.6bn
Q1 20241 holders, $9.7m31 holders, $29.8bn
Q2 20241 holders, $7.0m29 holders, $33.4bn
Q3 20241 holders, $5.9m27 holders, $33.5bn
Q4 20241 holders, $6.8m26 holders, $28.5bn
Q1 20251 holders, $5.9m21 holders, $35.4bn
Q2 20252 holders, $10m21 holders, $32.3bn
Q3 20251 holders, $1.9m22 holders, $25.9bn
Q4 20252 holders, $16m26 holders, $31.8bn
Q1 20262 holders, $18m25 holders, $31.8bn
Q2 20262 holders, $17m26 holders, $34.6bn
NATR

Natures Sunshine Prods Inc

Holders
2
Reported value
$17m
Buyers
10
Sellers
7

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NATR (1)

First Eagle Investment Management LLC

Only VRTX (25)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →